Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 20/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.49 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | FPR1 | P21462 | 1/20 | 0.48 |
| ▸ | TACR3 | P29371 | 1/20 | 0.48 |
| ▸ | GPR183 | P32249 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.48 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5412788 | 1.00 | TACR1 (0.56) | TACR1KCNH2NR1I2NR3C1CYP3A4 | |
| SCHEMBL6615409 | 1.00 | TACR1 (0.56) | TACR1KCNH2NR1I2NR3C1CYP3A4 | |
| SCHEMBL6435565 | 1.00 | TACR1 (0.56) | TACR1KCNH2NR1I2NR3C1CYP3A4 | |
| SCHEMBL5412707 | 1.00 | TACR1 (0.56) | TACR1KCNH2NR1I2NR3C1CYP3A4 | |
| SCHEMBL5413408 | 1.00 | TACR1 (0.56) | TACR1KCNH2NR1I2NR3C1CYP3A4 | |
| SCHEMBL6990518 | 0.91 | TACR1 (0.47) | TACR1 | |
| SCHEMBL6990250 | 0.91 | TACR1 (0.47) | TACR1 | |
| SCHEMBL6994101 | 0.91 | TACR1 (0.47) | TACR1 | |
| SCHEMBL7550074 | 0.90 | TACR1 (0.45) | TACR1KCNH2NR1I2NR3C1CYP3A4 | |
| SCHEMBL7547903 | 0.90 | TACR1 (0.45) | TACR1KCNH2NR1I2NR3C1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1603901-B1 | TETRAHYDROPYRAN COMPOUNDS AS TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME (GB) | 2008-10-15 | — | — | EP | disclosed |
| US-7393858-B2 | Tetrahydropyran compounds as tachykinin antagonists | MERCK SHARP & DOHME LTD. (GB) | 2008-07-01 | — | — | US | disclosed |
| US-20060172999-A1 | Tetrahydropyran compounds as tachykinin antagonists | MERCK SHARP & DOHME LTD. (GB) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060172999-A1 | Tetrahydropyran compounds as tachykinin antagonists | NPSR1, NPY1R, OPRL1 | TACR1 23/4885KCNH2 176/4885NR1I2 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.